SNORD20: SNORD20 is a small nucleolar RNA (snoRNA) that is significantly upregulated in gallbladder cancer (GBC) tissue [PMC5386738]. It is also among the top upregulated differentially expressed genes (CDEGs) in GBC tissue [PMC8319719]. SNORD20 is expressed in glioblastoma cell lines and occupies the eighth place among the most expressed RNAs [PMC7461500]. It shows a peak of CLIP reads at the D box [PMC4053766]. SNORD20 is also found to be enriched in snoRNA-derived small nucleolar RNA fragments (snoRFs) [PMC9624364]. In addition to GBC, SNORD20 has been identified in lung tissues of patients with pulmonary arterial hypertension (PAH) and primary acute myeloid leukemia (AML1-ETO+) samples with high leukemia stem cell content [PMC8346036] [PMC8629011]. SNORD20 represents over 40% of the total snoRNAs found in EV-enriched sweat, and its main role is the modification of rRNA through 2'-O-methylation [PMC8188706]. It has been overexpressed in HeLa cells to study its role, along with other control snoRNAs that are not associated with mRNA 3' processing complex [PMC5587809]. Defects in the nucleolin gene, which gives rise to SNORD20, have been linked to C9ORF72 repeat-related amyotrophic lateral sclerosis (ALS)100 [PMC5884852]. Overall, SNORD20 plays a role in various cancer types and has implications for RNA modification and disease pathology.